Stephen H Nantel
Overview
Explore the profile of Stephen H Nantel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
281
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stubbins R, Stamenkovic M, Roy C, Rodrigo J, Chung S, Kuchenbauer F, et al.
Eur J Haematol
. 2022 Feb;
108(5):437-445.
PMID: 35122325
Objectives: Acute myeloid leukaemia (AML) is a disease of older adults, who are vulnerable to socio-economic factors. We determined AML incidence in older adults and the impact of socio-economic factors...
2.
Cherniawsky H, Alahwal H, Abou Mourad Y, Forrest D, Gerrie A, Kuchenbauer F, et al.
Clin Lymphoma Myeloma Leuk
. 2021 Apr;
21(7):476-482.
PMID: 33814336
Despite improvements in therapy, approximately 5% of patients who undergo autologous stem cell transplantation (ASCT) experience early mortality (EM), death within 1 year of transplant (EM post-ASCT). Such patients tend...
3.
Kodad S, Sutherland H, Limvorapitak W, Abou Mourad Y, Barnett M, Forrest D, et al.
Clin Lymphoma Myeloma Leuk
. 2019 Nov;
19(12):784-790.
PMID: 31678079
Background: Autologous stem cell transplant (ASCT) is the preferred consolidation strategy to treat eligible patients with multiple myeloma (MM) and related plasma cell dyscrasias. Given the increasing volume of patients...
4.
Tsang E, Villa D, Loscocco F, Visani G, Power M, Guiducci B, et al.
Bone Marrow Transplant
. 2018 Sep;
54(3):481-484.
PMID: 30171222
No abstract available.
5.
Limvorapitak W, Barnett M, Hogge D, Forrest D, Nevill T, Narayanan S, et al.
Clin Lymphoma Myeloma Leuk
. 2018 Aug;
18(11):e481-e491.
PMID: 30100330
Introduction: Optimal post-remission therapy (PRT) for intermediate risk acute myeloid leukemia remains an area of ongoing research. We aimed to retrospectively compare outcomes following autologous stem cell transplantation (autoSCT) with...
6.
Zhu K, Song K, Connors J, Leitch H, Barnett M, Ramadan K, et al.
Br J Haematol
. 2018 May;
181(6):782-790.
PMID: 29741758
Treatment of Burkitt lymphoma (BL) with intensive, multi-agent chemotherapy with aggressive central nervous system (CNS) prophylaxis results in high cure rates, although no regimen is standard of care. We examined...
7.
Nair A, Barnett M, Broady R, Hogge D, Song K, Toze C, et al.
Biol Blood Marrow Transplant
. 2015 Apr;
21(8):1437-44.
PMID: 25865648
Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only known curative therapy for chronic myeloid leukemia (CML); however, it is rarely utilized given the excellent long-term results with tyrosine kinase...
8.
Sun H, Savage K, Karsan A, Slack G, Gascoyne R, Toze C, et al.
Clin Lymphoma Myeloma Leuk
. 2015 Feb;
15(6):341-8.
PMID: 25656914
Background: Double-hit lymphoma is characterized by the presence of concurrent MYC (myelocytomatosis oncogene) and BCL2 (B-cell lymphoma 2) gene rearrangements. Prognosis is poor with standard chemoimmunotherapy. Since 2003, the British...
9.
Abou Mourad Y, Bhargava R, Bruyere H, Gillian T, Barnett M, Forrest D, et al.
Clin Lymphoma Myeloma Leuk
. 2012 Oct;
13(3):281-6.
PMID: 23098889
Background: Diagnostic karyotype and molecular studies represent the most powerful prognostic indicators in acute myeloid leukemia and provide the framework for risk stratification. Risk stratification in ALL has also a...
10.
Toze C, Dalal C, Nevill T, Gillan T, Abou Mourad Y, Barnett M, et al.
Br J Haematol
. 2012 May;
158(2):174-185.
PMID: 22640008
The curative potential of allogeneic haematopoietic stem cell transplant (allo HSCT) in chronic lymphocytic leukaemia CLL is established, with a demonstrated role for graft-versus-leukaemia and less certainty for other factors...